June 13, 2016
3 min watch
Save
VIDEO: A look at results from phase 3 studies of baricitinib for RA treatment
LONDON — At the EULAR Annual Congress, Peter C. Taylor, MA, PhD, FRCP, discussed a study which looked at phase 3 studies of baricitinib. He said the patient-reported outcomes showed there were statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA).